scholarly journals Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer

1993 ◽  
Vol 67 (6) ◽  
pp. 1423-1429 ◽  
Author(s):  
JL Pujol ◽  
EH Cooper ◽  
M Lehmann ◽  
DA Purves ◽  
M Dan-Aouta ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Evaluation ◽  
Cell Lung Cancer ◽  
Tumour Marker ◽  
Small Cell ◽  
Small Cell Lung ◽  
Ca 242 ◽  
Serum Tumour Marker ◽  
Serum Tumour

The serum tumour marker Ca19-9 in non-small cell lung cancer (NSCLC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e18535-e18535
Author(s):  
Michael Vaslamatzis ◽  
Elisabeth Patila ◽  
Charalampia P. Margari ◽  
Theodoros K. Tegos ◽  
Nektarios Alevizopoulos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumour Marker ◽  
Small Cell ◽  
Small Cell Lung ◽  
Serum Tumour Marker ◽  
Serum Tumour

Prognostic value of Platelet-to-Lymphocyte Ratio (PLR) and IL-6 in patients with small cell lung cancer

2018 ◽  
Vol 54 (3) ◽  
pp. 137-144
Author(s):  
Ewa Wójcik ◽  
Zofia Stasik ◽  
Urszula Rychlik ◽  
Jadwiga Tarapacz ◽  
Jan Kanty Kulpa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumour Marker ◽  
Small Cell ◽  
Disease Stage ◽  
Small Cell Lung ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Favourable Prognosis

Background: In order to identify patients with the most favourable prognosis, the effect of baseline level of interleukin-6 (IL-6) and platelet-to-lymphocyte ratio (PLR) on survival was analysed in patients with small cell lung cancer.<br>Material and Methods: 159 patients with small cell lung cancer were enrolled. Full blood count enabling computing the PLR, as well as NSE, ProGRP and IL-6 levels were done in all participants.<br>Results: We demonstrated significant effect of disease stage, performance status, sex, initial NSE, ProGRP and IL-6 levels as well as PLR on survival of patients with SCLC. In subgroups with normal initial levels of ProGRP (below 50.36 ng/L) and NSE (below 20.95 μg/L), the IL-6 level above 6.0 ng/L worsens the prognosis by 28% and 29%, respectively. In a subgroup with elevated initial ProGRP, the difference in survival between patients with normal vs elevated IL-6 level at baseline was 25%, whereas in a subgroup with elevated initial NSE it was 14%. The between-subgroup differences in PLR were less considerable. There was a significant effect of PLR on patient survival in a subgroup with normal initial NSE level and elevated initial ProGRP level.<br>Conclusion: In subgroups of SCLC patients identified based on initial tumour marker levels, IL-6 level can be a source of reliable prognostic information, whereas the effect of PLR is less marked. Patients with normal tumour marker levels and IL-6 below 6 ng/L at baseline have the most favourable prognosis.

Clinical evaluation of proton radiotherapy for non–small-cell lung cancer

2003 ◽  
Vol 56 (1) ◽  
pp. 7-13 ◽  
Author(s):  
Yoshiyuki Shioyama ◽  
Koichi Tokuuye ◽  
Toshiyuki Okumura ◽  
Kenji Kagei ◽  
Shinji Sugahara ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Evaluation ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Proton Radiotherapy ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document